Global High Content Screening (HCS) Market Growth (Status and Outlook) 2023-2029

Global High Content Screening (HCS) Market Growth (Status and Outlook) 2023-2029

High-content screening (HCS) technology involves imaging-based multi-parametric analysis at the single-cell level. This technology was initially developed to complement biological high throughput screening in drug discovery. HCS analyses phenotypic changes in cellular samples.

LPI (LP Information)' newest research report, the “High Content Screening (HCS) Industry Forecast” looks at past sales and reviews total world High Content Screening (HCS) sales in 2022, providing a comprehensive analysis by region and market sector of projected High Content Screening (HCS) sales for 2023 through 2029. With High Content Screening (HCS) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world High Content Screening (HCS) industry.

This Insight Report provides a comprehensive analysis of the global High Content Screening (HCS) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on High Content Screening (HCS) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global High Content Screening (HCS) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for High Content Screening (HCS) and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global High Content Screening (HCS).

The global High Content Screening (HCS) market size is projected to grow from US$ 583.1 million in 2022 to US$ 1039.5 million in 2029; it is expected to grow at a CAGR of 8.6% from 2023 to 2029.

Owing to enhanced toxicity studies, demand for novel technologies in cell analysis is increasing rapidly across the globe. Instruments with enhanced cell imaging and analysis are preferred for early as well as later stages of the drug discovery process. This is expected to fuel the demand for High Content Screening (HCS) instruments in the near future. Also, increasing government support for life sciences research and increasing progress towards establishment of innovation and research-based biotechnology industries, primarily in countries such as China and India, is expected to contribute towards increased growth rate during the forecast period.

This report presents a comprehensive overview, market shares, and growth opportunities of High Content Screening (HCS) market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Cell Imaging & Analysis System
Flow Cytometry
Consumable
Software
Service

Segmentation by application
Primary & Secondary Screening
Toxicity Studies
Target Identification & Validation

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Becton, Dickinson and Company
GE Healthcare
Danaher
PerkinElmer
Thermo Fisher Scientific

Please note: The report will take approximately 2 business days to prepare and deliver.